Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE005 (FRA) (Dr. Muller)
· consented 2022-07-26
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 55); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 111); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 120); relationship: Y
mild
assessed
2026-08-18
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 126); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.